GlassScriptPhysician profile
Jacqueline Tuton
NPI 1669915690
$10,468.13
in general payments reported to CMS, 2019-2025
14 companies · $1,492 in 2025
The $1,492 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.24 · 2022: $330 · 2023: $2,287 · 2024: $6,277 · 2025: $1,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,232 · Travel and Lodging: $3,029 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,365 · Education: $279 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,232.41 |
| Travel and Lodging | $3,028.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,365.00 |
| Education | $279.49 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $4,117.56 | 2021-2025 | |
| Inspire Medical Systems, INC. | $2,716.78 | 2022-2025 | Inspire |
| Zoll Respicardia, INC. | $1,594.28 | 2023 | Remede System |
| Harmony Biosciences LLC | $786.05 | 2021-2025 | Wakix |
| Vanda Pharmaceuticals INC. | $475.89 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $246.82 | 2024-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $171.07 | 2023-2025 | Sunosi |
| Abbvie INC. | $114.87 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $81.20 | 2023-2024 | Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $41.12 | 2023-2024 | Lumryz |
| Alpha Cognition USA, INC. | $36.58 | 2025 | Zunveyl |
| Neurocrine Biosciences, INC. | $34.71 | 2025 | |
| Merck Sharp & Dohme LLC | $30.21 | 2022-2023 | Belsomra |
| Lilly USA, LLC | $20.99 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Tuton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.